HYDRATED CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
This invention relates crystalline hydrates of N-[3-fluoro-4-({6-(methyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]quinolin-4-yl }oxy)phenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Compound (I). The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline hydrate of Compound (I) and a pharmaceutically acceptable excipient.Cette invention concerne des hydrates cristallins de N-[3-fluoro-4-({6-(méthyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]quinolin-4-yl }oxy)phényl]-N-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, Composé (I). Linvention concerne aussi des procédés pour le traitement du cancer par lexploitation de la modulation de lactivité protéine kinase. Linvention concerne également des compositions pharmaceutiques comprenant un hydrate cristallin du Composé (I) et un excipient pharmaceutiquement acceptable.
